SION as reported
- Net Income
- −$97M
Net Income · +28% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$76M
Free Cash Flow · +19% year on year · trailing twelve months to Q2 2026
- EPS
- −$2.17
EPS · −100% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net Income | −$97M | +28% | Q2 2026 |
| EPS | −$2.17 | −100% | Q2 2026 |
| ROE | −28% | n/a | Q2 2026 |
| ROA | −27% | n/a | Q2 2026 |
| Free Cash Flow | −$76M | +19% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Sionna Therapeutics, Inc. (SION) - Net IncomeNet IncomeSionna Therapeutics, Inc. (SION)